• Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction 

      Løken-Amsrud, Kristin Ingeleiv; Myhr, Kjell-Morten; Bakke, Søren Jacob; Beiske, Antonie Giæver; Bjerve, Kristian S; Bjørnarå, Bård T.; Hovdal, Harald Olav; Lilleås, Finn; Midgard, Rune; Pedersen, Tom; Saltyte Benth, Jurate; Torkildsen, Øivind; Wergeland, Stig; Holmøy, Trygve (Peer reviewed; Journal article, 2013-01-22)
      Objective: Alpha-tocopherol is the main vitamin E compound in humans, and has important antioxidative and immunomodulatory properties. The aim of this study was to study alpha-tocopherol concentrations and their relationship ...
    • Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model 

      Wergeland, Stig; Torkildsen, Øivind; Myhr, Kjell-Morten; Aksnes, Lage; Mørk, Sverre; Bø, Lars (Peer reviewed; Journal article, 2011-10-20)
      Vitamin D is emerging as a probably important environmental risk factor in multiple sclerosis, affecting both susceptibility and disease progression. It is not known to what extent this effect is due to a modulation of ...
    • Fingolimod does not enhance cerebellar remyelination in the cuprizone model 

      Alme, Maria Nordheim; Nystad, Agnes Elisabeth; Bø, Lars; Myhr, Kjell-Morten; Vedeler, Christian A.; Wergeland, Stig; Torkildsen, Øivind (Journal article, 2015-08)
      Fingolimod (FTY720) is approved for treatment of relapsing–remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but in vivo animal studies have not detected ...
    • Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity 

      Holmøy, Trygve; Løken-Amsrud, Kristin Ingeleiv; Bakke, Jacob; Beiske, Antonie Giæver; Bjerve, Kristian S; Hovdal, Harald Olav; Lilleås, Finn; Midgard, Rune; Pedersen, Tom; Saltyte Benth, Jurate; Torkildsen, Øivind; Wergeland, Stig; Myhr, Kjell-Morten; Michelsen, Annika; Aukrust, Pål; Ueland, Thor (Peer reviewed; Journal article, 2013-09-19)
      Background. Serum markers of inflammation are candidate biomarkers in multiple sclerosis (MS). ω-3 fatty acids are suggested to have anti-inflammatory properties that might be beneficial in MS. We aimed to explore the ...
    • Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis 

      Wesnes, Kristin; Myhr, Kjell-Morten; Riise, Trond; Stokke, Silje Agnethe; Torkildsen, Øivind; Wergeland, Stig; Holmøy, Trygve; Midgard, Rune; Bru, Alla Nikolajevna S; Edland, Astrid; Eikeland, Randi; Gosal, Sonia; Harbo, Hanne Flinstad; Kleveland, Grethe; Sørenes, Yvonne; Øksendal, Nina; Bjørnevik, Kjetil Lauvland (Journal article; Peer reviewed, 2021)
      Background: Low vitamin D levels, tobacco use and high body mass index (BMI) have been linked to adverse disease outcomes in multiple sclerosis (MS), but their influence on long-term disability progression remains unclear. ...
    • Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model 

      Fjær, Sveinung; Bø, Lars; Myhr, Kjell-Morten; Torkildsen, Øivind; Wergeland, Stig (Peer reviewed; Journal article, 2015-03-02)
      Magnetization transfer ratio (MTR) is a magnetic resonance imaging (MRI) method which may detect demyelination not detected by conventional MRI in the central nervous system of patients with multiple sclerosis (MS). A ...
    • Neurofilament light chain predicts disease activity in relapsing-remitting MS 

      Varhaug, Kristin Nielsen; Barro, Christian; Bjørnevik, Kjetil Lauvland; Myhr, Kjell-Morten; Torkildsen, Øivind; Wergeland, Stig; Bindoff, Laurence; Kuhle, Jens; Vedeler, Christian A. (Peer reviewed; Journal article, 2018)
      Objective: To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods: A cohort of 85 patients with RRMS were followed ...
    • No association of tobacco use and disease activity in multiple sclerosis 

      Kvistad, Silje; Myhr, Kjell-Morten; Holmøy, Trygve; Saltyte Benth, Jurate; Løken-Amsrud, Kristin Ingeleiv; Wergeland, Stig; Beiske, Antonie Giæver; Bjerve, Kristian S; Hovdal, Harald Olav; Lilleås, Finn; Midgard, Rune; Pedersen, Tom; Bakke, Søren Jacob; Torkildsen, Øivind (Peer reviewed; Journal article, 2016-08)
      Objective: To study whether tobacco use is associated with MRI and clinical disease activity in patients with multiple sclerosis (MS). Methods: Prospective cohort study of 87 patients with relapsing-remitting MS originally ...
    • Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study 

      Eid, Karine; Torkildsen, Øivind Fredvik Grytten; Aarseth, Jan Harald; Flemmen, Heidi Øyen; Holmøy, Trygve; Lorentzen, Åslaug Rudjord; Myhr, Kjell-Morten; Riise, Trond; Simonsen, Cecilia Smith; Torkildsen, Cecilie Fredvik; Wergeland, Stig; Willumsen, Johannes Sverre; Øksendal, Nina; Gilhus, Nils Erik; Bjørk, Marte-Helene (Journal article; Peer reviewed, 2021)
      Objective: To assess the occurrence of perinatal depression and anxiety in women before and after diagnosis of multiple sclerosis (MS). Methods: 114,629 pregnant women were included in the Norwegian Mother, Father and Child ...
    • Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis 

      Norborg, Hilde; Riise, Trond; Myhr, Kjell-Morten; Torkildsen, Nina Agnethe Grytten; Wergeland, Stig (Journal article; Peer reviewed, 2021)
      Background For patients with MS, medication switches increase the risk of disease reactivation. Objective Compare discontinuation rates due to treatment failure or side effects between teriflunomide and dimethyl ...
    • Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study 

      Torgauten, Hilde Marie; Myhr, Kjell-Morten; Wergeland, Stig; Bø, Lars; Aarseth, Jan Harald; Torkildsen, Øivind (Journal article; Peer reviewed, 2021-01-31)
      Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy ...